

# Adam Bisaga

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7858494/adam-bisaga-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74  
papers

2,743  
citations

32  
h-index

50  
g-index

80  
ext. papers

3,066  
ext. citations

5.5  
avg, IF

5.14  
L-index

#	Paper	IF	Citations
74	Cognitive deficits predict low treatment retention in cocaine dependent patients. <i>Drug and Alcohol Dependence</i> , <b>2006</b> , 81, 313-22	4.9	314
73	Cerebral glucose metabolism in women with panic disorder. <i>American Journal of Psychiatry</i> , <b>1998</b> , 155, 1178-83	11.9	112
72	Development of a Cascade of Care for responding to the opioid epidemic. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2019</b> , 45, 1-10	3.7	111
71	The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. <i>Psychopharmacology</i> , <b>2001</b> , 157, 1-10	4.7	101
70	Cognition, commitment language, and behavioral change among cocaine-dependent patients. <i>Psychology of Addictive Behaviors</i> , <b>2008</b> , 22, 557-62	3.4	88
69	In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. <i>Drug and Alcohol Dependence</i> , <b>2000</b> , 59, 1-15	4.9	82
68	Developing an opioid use disorder treatment cascade: A review of quality measures. <i>Journal of Substance Abuse Treatment</i> , <b>2018</b> , 91, 57-68	4.2	79
67	Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2012</b> , 38, 187-99	3.7	78
66	Acute effects of memantine in combination with alcohol in moderate drinkers. <i>Psychopharmacology</i> , <b>2004</b> , 172, 16-24	4.7	69
65	Acute interaction of baclofen in combination with alcohol in heavy social drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2009</b> , 33, 19-30	3.7	68
64	Interaction between naltrexone and oral THC in heavy marijuana smokers. <i>Psychopharmacology</i> , <b>2003</b> , 166, 77-85	4.7	67
63	A randomized placebo-controlled trial of gabapentin for cocaine dependence. <i>Drug and Alcohol Dependence</i> , <b>2006</b> , 81, 267-74	4.9	65
62	Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 459-467	11.9	60
61	A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. <i>Addiction</i> , <b>2013</b> , 108, 1084-94	4.6	60
60	Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 950-6	7.9	59
59	Reinstatement of morphine-conditioned reward is blocked by memantine. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 160-70	8.7	58
58	The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 154, 38-45	4.9	57

57	Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 159, 53-60	4.9	56
56	From AIDS to Opioids - How to Combat an Epidemic. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 813-5	59.2	55
55	Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. <i>American Journal on Addictions</i> , <b>2009</b> , 18, 301-8	3.7	45
54	Management of relapse in naltrexone maintenance for heroin dependence. <i>Drug and Alcohol Dependence</i> , <b>2007</b> , 91, 289-92	4.9	45
53	Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder. <i>European Neuropsychopharmacology</i> , <b>2008</b> , 18, 794-802	1.2	43
52	A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. <i>Drug and Alcohol Dependence</i> , <b>2010</b> , 111, 97-104	4.9	42
51	A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 129-137	11.9	42
50	Effect of glutamate receptor antagonists on N-methyl-D-aspartate- and (S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced convulsant effects in mice and rats. <i>European Journal of Pharmacology</i> , <b>1993</b> , 242, 213-20	5.3	40
49	Individual behavioral differences and ethanol consumption in Wistar rats. <i>Physiology and Behavior</i> , <b>1993</b> , 54, 1125-31	3.5	40
48	The acute effects of gabapentin in combination with alcohol in heavy drinkers. <i>Drug and Alcohol Dependence</i> , <b>2006</b> , 83, 25-32	4.9	36
47	Recognition cue in the rat's social memory paradigm. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , <b>1991</b> , 2, 315-27	1.6	36
46	Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial. <i>Journal of Dual Diagnosis</i> , <b>2009</b> , 5, 41-56	2.4	35
45	Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 2233-48	5.9	34
44	Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. <i>Psychopharmacology</i> , <b>2020</b> , 237, 2233-2255	4.7	32
43	Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?. <i>Drug and Alcohol Dependence</i> , <b>2013</b> , 133, 80-5	4.9	32
42	A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. <i>American Journal on Addictions</i> , <b>2016</b> , 25, 603-609	3.7	32
41	A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. <i>Journal of Substance Abuse Treatment</i> , <b>2014</b> , 46, 546-52	4.2	30
40	A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. <i>Drug and Alcohol Dependence</i> , <b>2011</b> , 119, e23-9	4.9	30

39	Memantine reduces consumption of highly palatable food in a rat model of binge eating. <i>Amino Acids</i> , <b>2011</b> , 40, 477-85	3.5	30
38	Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement. <i>Drug and Alcohol Dependence</i> , <b>2013</b> , 128, 77-82	4.9	27
37	Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 187, 171-178	4.9	26
36	Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. <i>American Journal on Addictions</i> , <b>2018</b> , 27, 177-187	3.7	26
35	Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1371-8	4.6	24
34	Utility of lead-in period in cocaine dependence pharmacotherapy trials. <i>Drug and Alcohol Dependence</i> , <b>2005</b> , 77, 7-11	4.9	23
33	Pioglitazone, a PPAR $\alpha$ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. <i>Pharmacology Biochemistry and Behavior</i> , <b>2017</b> , 163, 90-100	3.9	21
32	A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. <i>American Journal on Addictions</i> , <b>2014</b> , 23, 68-75	3.7	21
31	A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. <i>American Journal on Addictions</i> , <b>2011</b> , 20, 441-6	3.7	21
30	Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 206, 107700	4.9	21
29	Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 147, 122-9	4.9	20
28	What should clinicians do as fentanyl replaces heroin?. <i>Addiction</i> , <b>2019</b> , 114, 782-783	4.6	19
27	Antisocial behavioral syndromes in cocaine and cannabis dependence. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2008</b> , 34, 405-14	3.7	18
26	Comparison of serum fatty acid ethyl esters and urinary 5-hydroxytryptophol as biochemical markers of recent ethanol consumption. <i>Alcohol and Alcoholism</i> , <b>2005</b> , 40, 214-8	3.5	17
25	Early abstinence in cocaine dependence: influence of comorbid major depression. <i>American Journal on Addictions</i> , <b>2007</b> , 16, 283-90	3.7	15
24	Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders. <i>American Journal on Addictions</i> , <b>2017</b> , 26, 319-325	3.7	14
23	Severity of dependence and motivation for treatment: comparison of marijuana- and cocaine-dependent treatment seekers. <i>Journal of Addictive Diseases</i> , <b>2006</b> , 25, 33-41	1.7	14
22	Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. <i>Psychology of Addictive Behaviors</i> , <b>2009</b> , 23, 47-55	3.4	13

21	Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?. <i>Drug and Alcohol Dependence</i> , <b>2014</b> , 144, 42-6	4.9	12
20	Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory. <i>Human Psychopharmacology</i> , <b>2007</b> , 22, 41-7	2.3	12
19	The PPAR $\alpha$ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. <i>Journal of Psychoactive Drugs</i> , <b>2018</b> , 50, 390-401	3.6	12
18	Baseline characteristics of patients predicting suitability for rapid naltrexone induction. <i>American Journal on Addictions</i> , <b>2015</b> , 24, 258-264	3.7	11
17	Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review. <i>Behaviour Research and Therapy</i> , <b>2018</b> , 111, 57-63	5.2	11
16	A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine. <i>Psychopharmacology</i> , <b>2008</b> , 199, 583-92	4.7	10
15	Insula damage and quitting smoking. <i>Science</i> , <b>2007</b> , 317, 318-9; author reply 318-9	33.3	10
14	Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , <b>2020</b> , 115, 239-246	4.6	10
13	Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice. <i>Drug and Alcohol Dependence</i> , <b>2008</b> , 95, 147-51	4.9	9
12	Comparison of clinical trial recruitment populations: treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participants. <i>Journal of Substance Abuse Treatment</i> , <b>2011</b> , 40, 426-30	4.2	8
11	Comparison of substance use milestones in cannabis- and cocaine-dependent patients. <i>Journal of Addictive Diseases</i> , <b>2012</b> , 31, 60-6	1.7	7
10	Medical Student Attitudes Toward Substance Use Disorders Before and After a Skills-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Curriculum. <i>Advances in Medical Education and Practice</i> , <b>2020</b> , 11, 455-461	1.5	6
9	A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2020</b> , 46, 289-296	3.7	5
8	Quetiapine treatment for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 218, 108366	4.9	4
7	Delay discounting and neurocognitive correlates among inner city adolescents with and without family history of substance use disorder. <i>Developmental Cognitive Neuroscience</i> , <b>2021</b> , 48, 100942	5.5	3
6	Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 370-7	4.6	3
5	Ling et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. <i>Addiction</i> , <b>2015</b> , 110, 875-6	4.6	2
4	Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 219, 108482	4.9	1

- 3 Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.. *Drug and Alcohol Dependence*, **2022**, 233, 109343 4.9 ○
- 2 Glutamatergic Agents for Nicotine Dependence **2006**, 167-176
- 1 Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. *Addiction*, **2020**, 115, 2188-2190 4.6